Genelux announces $20m public offering to fund corporate purposes.

Thursday, Jan 8, 2026 9:32 am ET1min read
GNLX--

Genelux Corporation has priced an underwritten public offering of 6.67 million shares of common stock at $3.00 per share, raising approximately $20.0 million. The net proceeds will be used for general corporate purposes, including research and development, clinical trial expenses, capital expenditures, and working capital.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet